{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:49:05Z","timestamp":1760150945542,"version":"build-2065373602"},"reference-count":39,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T00:00:00Z","timestamp":1643414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004329","name":"Slovenian research agency","doi-asserted-by":"publisher","award":["P1-0208 and NC-0004"],"award-info":[{"award-number":["P1-0208 and NC-0004"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Regional Development Plan","award":["EATRIS TRI.SI"],"award-info":[{"award-number":["EATRIS TRI.SI"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Anti-CD20 monoclonal antibodies (MAbs) have revolutionized the treatment of B-cell leukemia and lymphoma. However, many patients do not respond to such treatment due to either deficiency of the complementary immune response or resistance to apoptosis. Other currently available treatments are often inadequate or induce major side effects. Therefore, there is a constant need for improved therapies. The prostaglandin E2 receptor 4 (EP4) receptor has been identified as a promising therapeutic target for hematologic B-cell malignancies. Herein, we report that EP4 receptor agonists PgE1-OH and L-902688 have exhibited enhanced cytotoxicity when applied together with anti-CD20 MAbs rituximab, ofatumumab and obinutuzumab in vitro in Burkitt lymphoma cells Ramos, as well as in p53-deficient chronic lymphocytic leukemia (CLL) cells MEC-1. Moreover, the enhanced cytotoxic effects of EP4 receptor agonists and MAbs targeting CD20 have been identified ex vivo on primary lymphocytes B obtained from patients diagnosed with CLL. Incubation of cells with PgE1-OH and L-902688 preserved the expression of CD20 molecules, further confirming the anti-leukemic potential of EP4 receptor agonists in combination with anti-CD20 MAbs. Additionally, we demonstrated that the EP4 receptor agonist PgE-1-OH induced apoptosis and inhibited proliferation via the EP4 receptor triggering in CLL. This work has revealed very important findings leading towards the elucidation of the anticancer potential of PgE1-OH and L-902688, either alone or in combination with MAbs. This may contribute to the development of potential therapeutic alternatives for patients with B-cell malignancies.<\/jats:p>","DOI":"10.3390\/ijms23031599","type":"journal-article","created":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T23:02:06Z","timestamp":1643497326000},"page":"1599","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Enhanced Cytotoxic Effects in B-Cell Leukemia and Lymphoma Following Activation of Prostaglandin EP4 Receptor and Targeting of CD20 Antigen by Monoclonal Antibodies"],"prefix":"10.3390","volume":"23","author":[{"given":"Tijana","family":"Markovi\u010d","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy, University of Ljubljana, SI-1000 Ljubljana, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Podgornik","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, University of Ljubljana, SI-1000 Ljubljana, Slovenia"},{"name":"Department of Haematology, University Medical Centre Ljubljana, SI-1000 Ljubljana, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9759-2801","authenticated-orcid":false,"given":"Damjan","family":"Avsec","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, University of Ljubljana, SI-1000 Ljubljana, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanja","family":"Nabergoj","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, University of Ljubljana, SI-1000 Ljubljana, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irena","family":"Mlinari\u010d-Ra\u0161\u010dan","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, University of Ljubljana, SI-1000 Ljubljana, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global Cancer Statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","article-title":"Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience","volume":"34","author":"Salles","year":"2017","journal-title":"Adv. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/leu.2014.146","article-title":"Complement deficiencies limit CD20 monoclonal antibody treatment efficacy in CLL","volume":"29","author":"Middleton","year":"2015","journal-title":"Leukemia"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1182\/asheducation-2004.1.163","article-title":"Chronic Lymphocytic Leukemia","volume":"2004","author":"Byrd","year":"2004","journal-title":"Hematology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1016\/j.molimm.2007.06.151","article-title":"Mechanisms of killing by anti-CD20 monoclonal antibodies","volume":"44","author":"Glennie","year":"2007","journal-title":"Mol. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1002\/ajh.25595","article-title":"Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment","volume":"94","author":"Hallek","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3324\/haematol.2008.001628","article-title":"Anti-CD20 monoclonal antibodies: Historical and future perspectives","volume":"95","author":"Lim","year":"2010","journal-title":"Haematologica"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.ctrv.2012.10.008","article-title":"Effector mechanisms of anti-CD20 monoclonal antibodies in B cell malignancies","volume":"39","author":"Okroj","year":"2013","journal-title":"Cancer Treat. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.2147\/DDDT.S212500","article-title":"Clinical application of obinutuzumab for treating chronic lymphocytic leukemia","volume":"13","author":"Luan","year":"2019","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1200\/JCO.2000.18.17.3135","article-title":"Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin\u2019s Lymphoma: Safety and Efficacy of Re-Treatment","volume":"18","author":"Davis","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1038\/sj.onc.1210365","article-title":"Rituximab-induced inhibition of antiapoptotic cell survival pathways: Implications in chemo\/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions","volume":"26","author":"Bonavida","year":"2007","journal-title":"Oncogene"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.beha.2011.02.009","article-title":"Rituximab resistance","volume":"24","author":"Rezvani","year":"2011","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3960\/jslrt.56.89","article-title":"Genetic and Epigenetic Modulation of CD20 Expression in B-Cell Malignancies: Molecular Mechanisms and Significance to Rituximab Resistance","volume":"56","author":"Tomita","year":"2016","journal-title":"J. Clin. Exp. Hematop."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/j.2042-7158.2012.01499.x","article-title":"EP4 receptor signalling in immature B cells involves cAMP and NF-\u03baB dependent pathways","volume":"64","author":"Prijatelj","year":"2012","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.prostaglandins.2011.04.001","article-title":"Prostaglandin EP4 receptor enhances BCR-induced apoptosis of immature B cells","volume":"95","author":"Prijatelj","year":"2011","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.drudis.2016.08.003","article-title":"Structural features of subtype-selective EP receptor modulators","volume":"22","author":"Jakopin","year":"2017","journal-title":"Drug Discov. Today"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ejphar.2014.08.039","article-title":"Chemo-sensitizing effects of EP4 receptor-induced inactivation of nuclear factor-\u03baB","volume":"742","author":"Gobec","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"114352","DOI":"10.1016\/j.bcp.2020.114352","article-title":"EP4 receptor agonist L-902688 augments cytotoxic activities of ibrutinib, idelalisib, and venetoclax against chronic lymphocytic leukemia cells","volume":"183","author":"Nabergoj","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.pharmthera.2013.03.006","article-title":"E-type prostanoid receptor 4 (EP4) in disease and therapy","volume":"138","author":"Konya","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/0090-6980(80)90070-2","article-title":"2-Decarboxy-2-hydroxymethyl prostaglandin E1 (TR4161), a prostaglandin bronchodilator of low tracheobronchial irritancy","volume":"19","author":"Gardiner","year":"1980","journal-title":"Prostaglandins"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/0090-6980(85)90095-4","article-title":"Bronchodilatory properties of 2-decarboxy-2-hydroxymethyl prostaglandin E1","volume":"29","author":"Nizankowska","year":"1985","journal-title":"Prostaglandins"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3987\/COM-04-S(P)47","article-title":"Discovery and Synthesis of a Potent, Selective and Orally Bioavailable EP4 Receptor Agonist","volume":"64","author":"Young","year":"2004","journal-title":"Heterocycles"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.neuropharm.2012.09.010","article-title":"Neuroprotection mediated by the EP4 receptor avoids the detrimental side effects of COX-2 inhibitors following ischaemic injury","volume":"65","author":"Akram","year":"2013","journal-title":"Neuropharmacology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3389\/fnins.2018.00089","article-title":"Protective Effects of L-902,688, a Prostanoid EP4 Receptor Agonist, against Acute Blood-Brain Barrier Damage in Experimental Ischemic Stroke","volume":"12","author":"Demars","year":"2018","journal-title":"Front. Neurosci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/bjp.2008.214","article-title":"Vasorelaxation induced by prostaglandin E2in human pulmonary vein: Role of the EP4receptor subtype","volume":"154","author":"Foudi","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"L349","DOI":"10.1152\/ajplung.00245.2017","article-title":"Prostanoid EP4 agonist L-902,688 activates PPAR\u03b3 and attenuates pulmonary arterial hypertension","volume":"314","author":"Li","year":"2018","journal-title":"Am. J. Physiol. Cell. Mol. Physiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/bph.14854","article-title":"Bronchodilation induced by PGE 2 is impaired in Group III pulmonary hypertension","volume":"177","author":"Ozen","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.pupt.2011.12.012","article-title":"PGE2 receptor (EP4) agonists: Potent dilators of human bronchi and future asthma therapy?","volume":"25","author":"Benyahia","year":"2012","journal-title":"Pulm. Pharmacol. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Murn, J., Mlinaric-Rascan, I., Vaigot, P., Alibert, O., Frouin, V., and Gidrol, X. (2009). A Myc-regulated transcriptional network controls B-cell fate in response to BCR triggering. BMC Genom., 10.","DOI":"10.1186\/1471-2164-10-323"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s12032-013-0759-5","article-title":"Killing of CLL and NHL cells by rituximab and ofatumumab under limited availability of complement","volume":"30","author":"Okroj","year":"2013","journal-title":"Med. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1007\/s00262-005-0686-1","article-title":"A DeImmunized chimeric anti-C3b\/iC3b monoclonal antibody enhances rituximab-mediated killing in NHL and CLL cells via complement activation","volume":"54","author":"Peng","year":"2005","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1158\/2326-6066.CIR-18-0319","article-title":"Cellular Cytotoxicity of Next-Generation CD20 Monoclonal Antibodies","volume":"6","author":"VanDerMeid","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"749","DOI":"10.4049\/jimmunol.0900632","article-title":"Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX","volume":"183","author":"Pawluczkowycz","year":"2009","journal-title":"J. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/cas.12918","article-title":"Gemcitabine enhances rituximab-mediated complement-dependent cytotoxicity to B cell lymphoma by CD20 upregulation","volume":"107","author":"Hayashi","year":"2016","journal-title":"Cancer Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1158\/1078-0432.CCR-15-1304","article-title":"Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy","volume":"22","author":"Skarzynski","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.ctrv.2015.07.003","article-title":"Obinutuzumab in hematologic malignancies: Lessons learned to date","volume":"41","author":"Illidge","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1080\/14728214.2021.1966414","article-title":"The future of antibody therapy in chronic lymphocytic leukemia","volume":"26","author":"Crombie","year":"2021","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol. Rev."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/3\/1599\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:11:16Z","timestamp":1760134276000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/3\/1599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,29]]},"references-count":39,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["ijms23031599"],"URL":"https:\/\/doi.org\/10.3390\/ijms23031599","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2022,1,29]]}}}